Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $5,125,630.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $539.54, for a total transaction of $5,125,630.00. Following the transaction, the chief executive officer directly owned 130 shares of the company’s stock, valued at approximately $70,140.20. This represents a 98.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

United Therapeutics Trading Up 0.6%

United Therapeutics stock opened at $536.12 on Friday. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $548.12. The firm has a market capitalization of $23.50 billion, a PE ratio of 19.22, a price-to-earnings-growth ratio of 1.92 and a beta of 0.84. The firm’s 50 day simple moving average is $486.67 and its 200 day simple moving average is $460.13.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating the consensus estimate of $6.78 by $0.92. The firm had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The business’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same period last year, the firm earned $6.19 EPS. Research analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Institutional Investors Weigh In On United Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. AXQ Capital LP raised its holdings in shares of United Therapeutics by 495.4% during the second quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company’s stock valued at $1,117,000 after acquiring an additional 3,235 shares in the last quarter. AE Wealth Management LLC increased its position in United Therapeutics by 396.3% during the 3rd quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock valued at $1,798,000 after purchasing an additional 3,424 shares during the period. Great Lakes Advisors LLC increased its position in United Therapeutics by 194.7% during the 3rd quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock valued at $1,888,000 after purchasing an additional 2,975 shares during the period. Optimize Financial Inc bought a new position in United Therapeutics in the 3rd quarter worth $444,000. Finally, Simplify Asset Management Inc. bought a new position in United Therapeutics in the 3rd quarter worth $8,351,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

UTHR has been the subject of several recent analyst reports. Oppenheimer boosted their target price on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. UBS Group lifted their price target on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. TD Cowen upped their price objective on shares of United Therapeutics from $525.00 to $575.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Finally, Royal Bank Of Canada raised their target price on shares of United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $548.09.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.